Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties.

In 2019, Silence was paid an ‘upfront’ US$20mln for the exclusive worldwide licence to short interfering ribonucleic acids (siRNAs) against one target, C3, and the option to licence siRNAs against two additional targets.

The gene silencing specialist said the latest payment related to development work on the SLN500 C3 targeting programme.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News

Latest News

The oil market remains in positive territory with sentiment and stronger fundamentals driving the trend. ...